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The incidence and prevalence of neurodegenerative diseases (ND) increase with life expectancy. This paper reviews the
role of oxidative stress (OS) in ND and pharmacological attempts to ﬁght against reactive oxygen species (ROS)-induced
neurodegeneration. Several mechanisms involved in ROS generation in neurodegeneration have been proposed. Recent articles
about molecular pathways involved in ROS generation were reviewed. The progress in the development of neuroprotective
therapies has been hampered because it is diﬃcult to deﬁne targets for treatment and determine what should be considered as
neuroprotective. Therefore, the attention was focused on researches about pharmacological targets that could protect neurons
against OS. Since it is necessary to look for genes as the ultimate controllers of all biological processes, this paper also tried to
identify gerontogenes involved in OS and neurodegeneration. Since neurons depend on glial cells to survive, recent articles about
the functioning of these cells in aging and ND were also reviewed. Finally, clinical trials testing potential neuroprotective agents
were critically reviewed. Although several potential drugs have been screened in in vitro and in vivo models of ND, these results
were not translated in beneﬁt of patients, and disappointing results were obtained in the majority of clinical trials.
1.Introduction
The incidence of neurodegenerative diseases (NDs) increases
with extended life expectancy. Age-related degenerative dis-
easesareincreasingtoepidemicproportionsinallindustrial-
ized countries. The rise in elderly populations is resulting in
an increased incidence of mild cognitive impairment, which
is characterized by a less severe (but abnormal) level of cog-
nitive impairment and a high risk for developing dementia.
The incidence and prevalence of severe cognitive impair-
ment is also rising. Alzheimer’s disease (AD) aﬀects approx-
imately 4.5 million Americans, projected to increase to 11
and to 16 million by 2050; Parkinson’s disease (PD) aﬄicts
approximately one million persons in the United States,
60,000 new cases are diagnosed every year, and its inci-
dence is projected to quadruple by 2040 [1]. PD represents
a growing socioeconomic burden on societies. In Spain, NDs
were included in the Strategic Action on Health, and the
Network Centres of Biomedical Research assigned C 6862
million to integrate 64 groups and 493 researchers working
in this ﬁeld [2].
The neuronal cell oxidative stress (OS) response has an
intense interest for neuroscientists because it is a hotspot on
neurodegeneration. The generation of reactive oxygen spe-
cies (ROS) and oxidative damage is believed to be involved in
the pathogenesis of neurodegenerative disorders. Biological
systems that require oxygen for life are always under various
levels of OS. The main ROS involved in neurodegeneration
are superoxide anion (O
−
2 ), hydrogen peroxide (H2O2), and
the highly reactive hydroxyl radical (HO
•). Furthermore,
reactive nitrogen species (RNS) such as nitric oxide (NO)
can also damage neurons. The free radical NO can react with2 Oxidative Medicine and Cellular Longevity
O
−
2 to produce peroxynitrite (ONOO
−), a powerful oxidant,
which may decompose to form HO
•. Oxidative stress results
from a misbalance between ROS generation and antioxidant
defenses. The widely accepted OS theory of aging postulates
thatitresultsfromaccumulationofoxidativedamages.There
is evidence that malnutrition, OS, and homocysteine-related
vitamins play a role in the pathogenesis of AD [3]. Dietary
antioxidant deﬁciency facilitated the induction of spreading
depression in rat brains by the photoactivation of riboﬂavin,
which generates ROS [4]. Oxidative damage has also been
associated with pathological neuronal loss in PD [5]a n d
Huntington’s disease (HD). Beyond AD, PD, and HD, there
are evidences pointing out the important role of OS in
other neurodegenerative disorders such as Machado-Joseph
disease (MJD) [6]. Therefore, OS provides a crucial link
between pathological pathways that occur independently in
distinct ND.
The progress in the development of neuroprotective
therapies has been hampered by several factors. Without
knowing the precise underlying mechanisms of cell death in
neurodegenerative disorders, such as PD and AD, it is dif-
ﬁcult to deﬁne targets for treatment and determine what
should be considered as neuroprotective. The development
of drugs that modify the progression of ND remains the
most important goal in the treatment of these disorders.
Drug screening in vitro is the ﬁrst step in drug discovery and
development. Once a potential candidate is found, it is tested
in vivo, in animal models, prior to be submitted to clinical
trials.Severaldrugshaveattractedattentionaspotentialneu-
roprotective agents in the laboratory, but clinical eﬃcacy for
neuroprotection remains unproven. This paper intends to
review advances made in the study about the role of OS
in ND and pharmacological attempts to ﬁght against ROS-
induced neurodegeneration.
2.MolecularMechanisms
Although not yet deﬁnitive, several possible mechanisms of
neurodegeneration have been proposed in the scientiﬁc lit-
erature. The mitochondrion has been identiﬁed as a major
source of ROS, and its dysfunction with time appears to con-
tribute to neural decay and ageing [7]. An important feature
of this theory is that it creates a possibility for intervention
to modify the rate and the conditions of ageing [8]. The
mitochondrion is a major site of cellular O
−
2 production,
mainly derived from Complex I due to partial reduction of
NADH-dehydrogenase bound FMN; and from Complex III
also due to partial reduction of ubiquinone/ubisemiquin-
one/ubiquinol, by transfer of one electron to O2 [9]. Based
in this theory, inhibitors of mitochondrial complexes are
currently used to induce OS creating in vitro and in vivo
models of ND, which are useful in drug screening.
Another mitochondrial source of ROS is the enzyme
family of monoamine oxidase (MAO; EC 1.4.3.4). These en-
zymes are bound to the outer mitochondrial membrane
and catalyze the oxidation of biogenic amine neurotrans-
mitters such as norepinephrine, dopamine, and 5-hydrox-
ytryptamine (serotonin), but they generate free radicals
during their activity. MAO-B catalyzes the oxidation of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to
MPP+, which inhibits mitochondrial complex I and initi-
ates biochemical, clinical, and neuropathological changes
analogous to those observed in idiopathic PD. 2-Amino-
6-triﬂuoromethoxybenzothiazole (riluzole), an Na+ chan-
nel blocker with antiglutamatergic activity, signiﬁcantly
prevented MPTP-induced reduction in striatal dopamine
and 3,4-dihydroxyphenylacetic acid levels in mice [10]. 3-
Nitropropionic acid, which blocks succinic dehydrogenase
(EC 1.3.99.1) in mitochondrial Complex II, produces patho-
logical changes and cell damages and induces apoptosis in
mouse striatal tissue [11]. Therefore, this compound has
been used as pharmacological tool in animal models to ad-
dress some of the metabolic modiﬁcations that might un-
derlie central neurodegeneration. The treatment of neurob-
lastoma cells (SK-N-MC) with low doses of antimycin A1,
which is a mitochondrial complex III inhibitor, and 2-deoxy-
D-glucosemoderatelyimpairedcellularfunctionsbyalonger
lasting modest OS, reduction of mitochondrial function and
reduced intracellular energy levels, simulating a slow chronic
eﬀect [12]. In this model, these same authors showed that
the Ginkgo biloba extract EGb 761 signiﬁcantly protected
cells against reduced glutathione (GSH) depletion. There is
a summing knowledge in scientiﬁc literature showing that
the neurodegeneration in PD is associated with a cascade of
events that includes OS, mitochondrial abnormalities, excit-
otoxity, protein accumulation, inﬂammation, and ultimately
apoptosis [13]. Therefore, preclinical strategies targeted in
mitochondrial ROS generation are useful to identify poten-
tial drug candidates.
Superoxide dismutases (SOD, EC 1.15.1.1) in the mito-
chondria (Mn-SOD) and cytoplasm (Cu/Zn-SOD) convert
O
−
2 to oxygen (O2)a n dH 2O2 (Figure 1). In turn, catalase
(EC 1.11.1.6) and glutathione peroxidases (EC 1.11.1.9) con-
vert H2O2 to water (Figure 1). These enzymes are critical
for preventing oxidative damages to cells. Thioredoxin and
glutathione thiol-based reducing systems are important
reductants of many oxidative stressors such as peroxides
[14]. Therefore, a biological approach to investigate whether
new drugs have molecular mechanism of actions targeted
on antioxidant enzymes seems to be an interesting strategy
in drug discovery. In addition, other antioxidant molecules,
such as α-tocopherol (vitamin E) improved the neurological
performance and brain mitochondrial functions in mice by
presumably decreasing mitochondrial protein and lipid oxi-
dation products [7]. Melatonin has also shown antioxidant
properties, since it reduced the levels of malondialdehyde
(MDA) plus 4-hydoxyalkenals, which are markers of lipid
peroxidation, in the hippocampus, cortex, and cerebellum
of rats exposed to 3000ppm thinner fumes (containing 66%
toluene) [15].
Mitochondria are not the only source of ROS involved
in neurodegeneration. Transition metal ions are capable
of stimulating free radical formation, and markers of OS
(Figure 2) precede pathologic lesions in AD, including senile
plaques and neuroﬁbrillary tangle [16]. The main features
of enhanced OS in the AD brain involve increased content
of reduced copper and iron capable of stimulating freeOxidative Medicine and Cellular Longevity 3
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Figure 1: Reactions catalyzed by superoxide dismutase (SOD), cat-
alase, and glutathione peroxidases. Superoxide dismutases (SOD)
convert O
−
2 to O2 and H2O2. Catalase and glutathione peroxidases
convert H2O2 to water. Protein structures represented in this ﬁgure
are available in the Protein Data Bank (PDB; http://www.rcsb
.org/pdb/home/home.do). PDB ID, are referred in brackets.
radical generation, increased carbonyls, protein and DNA
oxidation, increased MDA and enhanced lipid peroxidation,
decreasedlevelsofcytochromecoxidase, increasedadvanced
glycation end products, ONOO
−, and heme oxygenase-1
[17].Themeasureofcarbonylcontentinproteinlysatesfrom
brain microvessels isolated from rats showed an increase in
vascular OS with age [18]. Studies performed on postmortem
substantia nigra from PD patients demonstrated increased
levelsofreducedironandMAO-Bactivity,OS,inﬂammatory
processes, glutamatergic excitotoxicity, NO synthesis, abnor-
mal protein folding and aggregation, reduced expression
of trophic factors, depletion of GSH, and altered calcium
homeostasis [5]. It has also been suggested that iron accu-
mulation may contribute to the OS-induced apoptosis re-
ported in both PD and PD dementia [19]. Furthermore, ATP
depletion or lipid and protein peroxidation induced by ROS
are also implicated in PD and can kill neurons by necrotic
processes [13]. Therefore, transition metals have been se-
lected as targets for the research and development of new
drugs.
In AD, the amyloid-β peptide (Aβ) is released into the
glutamatergic synapse cleft where it has the potential to
react with copper and zinc to form oxidized, crosslinked
soluble aggregates, and precipitated amyloid [20]. Although
in the central nervous system (CNS) Zn
2+ is a component
of proteins involved in the defense against OS [21] and is
implicated in the regulation of channels and receptors, this
cation can also act as a trigger for neuronal loss in several
neurological conditions linked to mitochondrial dysfunction
and OS [22]. A major physiological role for Zn
2+ may be the
modulationofcellsignalingcascades,especiallythoseinvolv-
ing protein phosphorylation [23]. The autophagy is reduced
or blocked in neurodegenerative conditions, including AD,
PD, HD, and Niemann-Pick type C disease. This is probably
modulated by zinc and metallothionein 3, associated with
activation of protein kinase C (PKC, EC 2.7.11.13), NADPH
oxidases (EC 1.6.3.1), extracellular-signal-regulated kinase
(ERK) 1/2 (EC 2.7.11.24), and poly ADP-ribose polymerase
(PARP, EC 2.4.2.30), causing oxidative neural necrosis [24]
(Figure 3). Heavy metals with no biological function, such
as mercury, are also potentially harmful to the human
brain. Mercury is a widespread natural and anthropogenic
environmental contaminant. Even though the mechanisms
underlying mercury toxicity are still unclear, it lowered the
catalase activity and increased the glutathione reductase (EC
1.8.1.7)activityinbrainhomogenatesofcontaminatedﬁshes
(Dicentrarchus labrax)[ 25]. However, there is no established
correlation between ND and exposure to heavy metals.
Proteins are one of the prime targets for oxidative
damage, and cysteine residues are particularly sensitive to
reversible and irreversible oxidation [26]. The level of pro-
tein-glutathione-mixed disulﬁdes is increased in the brain of
old rats, which represents a reliable index of thiol-directed
OS [27]. Although apomorphine is a potent dopaminergic
agonist largely used in the treatment of PD, it covalently
binds to proteins, probably in cysteine residues, because this
amino acid prevented the formation of adducts [28]. The
pathologic interaction of cerebral Aβ with transition metals
such as zinc, copper, or iron is possibly a neurochemical
factor that initiates Aβ deposition [29]. The toxic eﬀects
that stem from the misassembly or aggregation of proteins
or peptides are collectively termed proteotoxicity [26]. A
deregulation of brain iron and cooper homeostasis is a key
factorto early neuropathological events in AD, including OS,
inﬂammatory processes, proteotoxicity, tau phosphorilation,
and neuronal cell cycle regulatory fail, leading to apoptosis
[21]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
EC 1.2.1.12) may also be a target, since massive OS caused in
vivobymethamphetamineinducestheformationofGAPDH
aggregates in mouse brain [30]. Proteins that appear to have
a key role in disease pathogenesis constitute targets for drug
discovery.
Oxidativestress,perturbedenergymetabolism,andalter-
ations of disease-related proteins result in Ca2+-dependent
synaptic dysfunction, impaired plasticity, and neuronal
demise [31]. The causes and consequences of OS in neurons
in AD are not fully understood, but considerable evidence
points to important roles for accumulation of Aβ upstream
of OS, and perturbed cellular Ca2+ homeostasis and energy
metabolism downstream of it [32]( Figure 4). On the other
hand, increased intracellular Ca2+ w o u l dl e a dt oa ni n c r e a s e
in mitochondria-derived ROS and RNS generation by dis-
turbing the respiratory chain and activating a series of en-
zymes, including neuronal NO synthases (EC 1.14.13.39)
and xanthine oxidases (EC 1.17.3.2), which catalyze ROS or
RNS formation by triggering the arachidonic acid cascade
[33]. NO activates the epsilon isoform of PKC, which in turn
activates the Src family of protein tyrosine kinases and tran-
scription factors with resultant upregulation of expression of
many genes and proteins [34]. Curiously, age-related mac-
ular degeneration, which is a late-onset, neurodegenera-
tive retinal disease, shares several clinical and pathological
features with AD, including stress stimuli such as OS and4 Oxidative Medicine and Cellular Longevity
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Figure 2: Oxidative damages induced by transition metals. Iron and copper can reduce oxygen leading to ROS generation and subsequent
oxidation of proteins, lipids, and nucleic acids.
inﬂammation [35]. Oxidative stress, protein aggregation and
redox activemetalionscanallbeconsideredpotential targets
for the treatment of neurodegeneration.
Although normal excitatory neurotransmission is essen-
tial for synaptic development and plasticity as well as learn-
ing and memory, the excessive stimulation of glutamatergic
receptors induces neurotoxicity and plays a role in ND. It is
known that the excitatory amino acid β-N-oxalyl-α,β-diam-
inopropionic acid binds to α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) receptors triggering motor
neuron degeneration by inducing OS and cell death [36].
The excessive nitrosative and OS that results from the hy-
peractivation of the AMPA-type glutamate receptors is
thought to trigger cellular signaling pathways leading to neu-
rodegenerative conditions [37]. Modiﬁcations in excitatory
glutamatergic neurotransmission provide a rational basis for
the discovery of new medicines.
Among the several environmental factors proposed for
AD, dietary risk and protective factors have been most com-
pelling. Diets rich in saturated fatty acids, alcohol, and
deﬁcient in antioxidants and vitamins appear to promote
the onset of the disease, while diets rich in unsaturated fatty
acids, vitamins, antioxidants, and wine likely suppress its
onset [38]. Actually, there is a great interest to study the
neuroprotective eﬀects of natural products obtained from
plants. The major lignans contained in sesame seeds are ses-
amin and episesamin. (1R,2S,5R,6S)-6-(3,4-dihydroxyphen-
yl)-2-(3,4-methylenedioxyphenyl)-3,7-dioxabicyclo-[3, 3,
0]octane (SC-1), (1R,2S,5R,6S)-2,6-bis(3,4-dihydroxyphen-
yl)-3,7-dioxabicyclo-[3,3,0]octane (SC-2), and (1R,2S,5R,
6R)- and (1R,2R,5R,6S)-6-(3,4-dihydroxyphenyl)-2-(3,4-me-
thylenedioxyphenyl)-3,7-dioxabicyclo-[3,3,0]octane(EC-1)
are derivatives of sesamin and episesamin that activatedOxidative Medicine and Cellular Longevity 5
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Figure 3: Cell death induced by zinc. Zinc modulates protein
kinases, which activates NADPH oxidase and PARP-1, leading to
necrosis.
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Figure 4: Neuronal demise in Alzheimer’s disease. The pathologic
interaction of cerebral Aβ with transition metals induces oxidative
stress,perturbedcellularCa
2+ homeostasis,andenergymetabolism,
which in turns generates more ROS leading to neuronal demise.
the nuclear factor-erythroid-2-related factor 2 (Nrf2)/an-
tioxidant response element (ARE) [39]. Nrf2 protein is a
Cap’n’Collar basic-region leucine zipper transcription factor
responsible for activating transcription of more than 100
known, mainly cytoprotective genes—the so-called “Nrf2
battery” [40]. The activation of Nrf2/ARE regulates the
Keap1
Nrf2
Proteasome-dependent
degradation
Nucleus
Nrf2
ARE
Induction of
antioxidant enzymes
Oxidative
Stress
Figure 5: Nrf2 regulates the expression of antioxidant enzymes.
Underphysiologicalconditions,Nrf2bindstoKeap1andundergoes
constitutive proteasome-dependent degradation. However, under
oxidative stress, Keap1 changes its conformation and releases Nrf2,
which moves to the nucleus and binds to ARE regulating the
expression of several antioxidant enzymes.
expression of antioxidant enzymes (Figure 5). Under un-
stressed conditions, Nrf2 binds to Kelch-like ECH-associated
protein 1 (Keap1) and undergoes constitutive proteasome-
dependent degradation. In the presence of OS, Keap1 chan-
ges its conformation and releases Nrf2, which moves to the
nucleus and binds to ARE. The induction of antioxidant
enzymes by activation of Nrf2/ARE signaling has been con-
sidered as a promising strategy to ﬁght against OS-related
diseases.Theexpressionand/oractivationofNrf2inneurons
c a nb es t r o n g l yp r o t e c t i v e[ 14] and provides an interesting
biological hypothesis to be tested and a starting point for the
identiﬁcation of molecules to do this.
3. Looking for New Neuroprotectants
Since there is no eﬀective drug in the control of ND, in
the next paragraphs some recent data on drug screening for
neuroprotectants were reviewed. Tanshinone IIA, one of the
keycomponentsofSalviamiltiorrhizaBungeroots,protected
primary rat cortical neurons against H2O2-induced cytotox-
icity in vitro [41]. The extract of Lonicera japonica Thumb.,
which is a shrub traditionally used in Korea and China,
also signiﬁcantly inhibited H2O2-induced SH-SY5Y human
neuroblastoma cell death [42]. Hydrogen peroxide induces
thephosphorylationoftheproteinkinaseAktandinactivates
ERK phosphorylation. Prosaposin, a multifunctional protein
with versatile neurotrophic activities, which is found in the
cerebrospinal ﬂuid, rescued PC12 cells from H2O2-induced
cytotoxicity through the regulation of Akt and ERK phos-
phorylation pathways [43]. The ethanol extract obtained6 Oxidative Medicine and Cellular Longevity
from leaves of the Eriobotrya japonica, which is a traditional
medicinal plant in East Asia, protected rat pheochromo-
cytoma PC12 cells against Aβ1–42-induced cytotoxicity and
formationofintracellularROS[44].Inthesediﬀerentinvitro
models, cells were severely injured with agents that promptly
induce fatal cellular damages. However, it is not known if
the protective eﬀects of these agents observed in vitro will
provide a suﬃcient therapeutic index in vivo.
Synthetic compounds have also been tested. 2-Ethoxy-
4,5-diphenyl-1,3-oxazyne-6-one presented neuroprotective
eﬀects against H2O2-induced PC12 cell death [45]. Another
reported neuroprotective agent is 5-chloro-7-iodoquinolin-
8-ol (clioquinol), which is an eﬀective iron chelator that
blocked the formation of H2O2 induced by Aβ [21]. How-
ever, since halogenated hydroxyquinolines possess neurotox-
ic side eﬀects, highly selective iron(III) hydroxypyridinone-
based ligands have been synthesized in a range of lipophilic-
ity to permit good blood-brain barrier (BBB) permeability
[46].Thecharacteristicofthese newmolecularentities needs
to be analyzed.
Actually, obesity is an important health care issue. There
is a growing appreciation that the complications of obesity
extend to the CNS. Deﬁcits in a learning task that is depen-
dent at least in part on hippocampal function were observed
in rats with obesity phenotype elicited by downregulation of
hypothalamic insulin receptor [47]. Furthermore, in a case-
control analysis, in which participants were drawn from the
Swedish Twin Registry, overweight and obesity at midlife
were related to dementia with odds ratios (95% CI) of 1.71
(1.30–2.25) and 3.88 (2.12–7.11), respectively [48].
In 16-month-old male C57BL/6 strain mice, which
received 2% cholesterol/daily by intraperitoneal injection for
16 weeks, a signiﬁcant increase in ROS was measured in
brain homogenates compared to control animals that did
not receive it, but interestingly, it was attenuated by daily
oral administration of the ﬂavonoid quercetin at doses of
60mg·Kg−1·day−1 [49].Dietarypolyphenols,suchasﬂavon-
oids, are derived from plants and are consumed in the forms
of fruits, vegetables, and wine. Baicalin is a ﬂavonoid that is
a component of Scutellaria baicalensis Georgi roots, which
have been widely used in China to treat stroke for thou-
sands of years. This compound protected human SH-SY5Y
neuroblastoma cells against Aβ-induced cytotoxicity and
H2O2 production [50]. Resveratrol is the most outstanding
representative of wine polyphenols. Resveratrol has neuro-
protective features in both in vitro and in vivo models of AD,
ischemicstroke, PD,HD,andepilepsy [9].Ithasbeenargued
that many of the neuroprotective actions in animal models
that are ascribed to natural botanical antioxidants, such
as ﬂavonoids, polyphenols, and tocopherols actually derive
from the pharmacological antagonism by these compounds
ofenzymesystemsthatproducereactiveoxidantspecies[51].
Quercetin and resveratrol activate the Nrf2/Keap1 signaling
pathway [40].
The pesticide rotenone is a naturally occurring plant
compound commonly used in vegetable gardens as insecti-
cide. Neurons exposed to rotenone (0.3μM) generated O
−
2 ,
an eﬀect that was inhibited by N-acetylcysteine [52]. The
rotenone-treated human dopaminergic cells SH-SY5Y are
a suitable model for investigating new possible therapeutic
targets for PD. Rhus verniciﬂua Stokes of the Anacardiaceae
family is commonly known as lacquer tree. The clinical ap-
plication of this plant has been limited because an allergenic
mixture of several derivatives of catechol, called urushiol,
causes severe contact dermatitis. However, it can be removed
during the extraction process. The pretreatment of SH-SY5Y
cells with the detoxiﬁed extract obtained from the bark of
this plant signiﬁcantly diminished rotenone-induced ROS
formation [53]. Molecules bearing the catechol group may
be neurotoxic by inducing OS depending on the concentra-
tion. The simplest catechol molecule, 1,2-dihydroxybenzene,
which is a benzene metabolite, killed neuroblastoma N2a
cells after 72 hours, when treated with concentrations of at
least 20μM, and presented an EC50 of 38μM, an eﬀect that
was signiﬁcantly prevented by L-cysteine [54]. The presence
of a catechol group in a molecule can interfere in both drug
eﬃcacy and safety.
The histone deacetylase (EC 3.5.1.98) of the family 6,
which catalyzes the deacetylation of lysine residues on histo-
ne and several other proteins such as α-tubulin, is another
potential therapeutic target. It seems that this enzyme is
involved in some ND, since its selective inhibition by mer-
captoacetamides protected neurons against the OS-induced
neurodegeneration [55]. This suggests that the molecular
mechanism of action based in the interaction between drugs
and this enzyme should provide a therapeutic eﬀect.
4. IsThereAnyRelationshipbetweenGenesand
OxidativeStress?
The term gerontogenes has been suggested to refer to any
genetic elements that are involved in aging [56]. Since it is
necessary to look for genes as the ultimate controllers of
all biological processes, it is important to identify geron-
togenes involved in ND. Furthermore, the maintenance of
optimal long-term health conditions is accomplished by a
complex network of longevity assurance processes which are
controlledbyvitagenes,suchasthosethatencodeheat-shock
proteins, thioredoxin, and the sirtuin protein systems [26].
This group of genes preserves cellular homeostasis during
stressful conditions. Omega-3 polyunsaturated fatty acids
have the ability to regulate several genes associated with OS,
apoptosis, as well as cell signaling and division, and may
constitute a therapeutic strategy for several CNS disorders,
although further clinical trials are needed to investigate it
[57].
Although most cases of AD are sporadic, 5–10% of AD
patients suﬀer from familial AD with an autosomal domi-
nant inheritance pattern. However, despite the overexpres-
sion of Aβ1–42 from birth, it is not the solely responsible fac-
tor for amyloid deposition, because it is not observed in
childhood. Zinc, copper, and iron have been implicated as
initiating factors due to high concentration gradients of
these metals in the cortex, hippocampus, and the cortical
vasculature—brain regions that are severely aﬀected by the
pathological lesions of AD [29].
The human MAO-A and MAO-B promoters cloned into
the luciferase reporter construct pGL3 were activated whenOxidative Medicine and Cellular Longevity 7
cotransfected with the nuclear orphan estrogen-related re-
ceptor α inHeLacells, but it was almost completely abolished
by the cotransfection with the parkin gene [58]. This means
that parkin may control OS by limiting the expression of
MAO, responsible for the oxidative deamination of dopam-
ine.Furthermore,upregulationofparkincancompensatefor
neuronal loss caused by PINK1 mutations at least in ﬂies, but
this mutation is also seen in cells from PD patients [59].
HDisafatalautosomaldominantneurodegenerativedis-
order of midlife onset involving the protein huntingtin (Htt)
that is expressed widely and heterogeneously in neurons
throughout the brain. This genetic disease is associated with
the degeneration of GABAergic striatal projection neurons
in the basal ganglia leading to movement disorders with
behavioralsymptoms forwhichthereis presentlynotherapy.
However, a direct pathway linking the genetic mutation to
neuronal degeneration has not been established. In PC12
cells modiﬁed to express mutant Htt, there was a caspase 3
(EC 3.4.22.56) activation, which was reduced by an indol-
ocarbazole analog (CEP-1347) [60]. The polyphenol ﬁsetin
also increased the survival of mutant PC12 cells [61]. Fur-
thermore, other genes seem to be regulated in HD cases like
MAO-A,whichwasfoundsigniﬁcantlyincreasedthroughout
the caudate and putamen, whereas MAO-B was even higher
compared to controls [62]. Therefore, MAO seems to be
involved in the induction of OS and lipid peroxidation. 4-
Hydroxy-2-nonenal (HNE), a highly reactive lipid peroxida-
tion product, is increased in caudate and putamen of human
HD brains [63]. HNE can irreversibly modify proteins by
binding covalently to cysteine, lysine, and histidine residues
[64]. Furthermore, under OS and in the presence of NO,
GAPDH undergoes posttranslational modiﬁcations, espe-
cially S-nitrosylation. The modiﬁed GAPDH is translocated
to the nucleus upon exposure to stressors and participates in
cell death. GAPDH has been found in nuclei of ﬁbroblasts
and in postmortem brains from patients with HD [30].
MJD/spinocerebellar ataxia type 3 is an autosomal dom-
inant spinocerebellar degeneration caused by polyglutamine
expansion in the ataxin-3 protein. It is characterized by cere-
bellar ataxia and pyramidal signs associated in varying de-
grees with a dystonic-rigid extrapyramidal syndrome or pe-
ripheral amyotrophy as major neurologic signs. Human neu-
roblastoma SK-N-SH cells transfected with the mutant
ataxin-3 presented lower total glutathione and GSH contents
than the wild type [6]. Furthermore, there was a decrease in
activities of glutathione reductase, catalase, and superoxide
dismutase, which suggests that these modiﬁed cells are prone
to damages under OS.
Although neurodegenerative disorders have a more com-
monlate-onset,insomeraregeneticdiseases,suchasjuvenile
neuronal ceroid lipofuscinosis (Batten disease), the neuro-
degeneration has an early onset, usually at 5–7 years. Even
in this juvenile neurodegenerative disease, OS is involved in
the pathological mechanism. Batten disease is caused by mu-
tations in the CLN3 gene that encodes a highly hydrophobic,
multispanning transmembrane protein of unknown func-
tion. In a CLN3 Drosophila mutant model, mutant ﬂies were
m o r es u s c e p t i b l et oO Si n d u c e db yH 2O2, diethylmaleate,
whichdepletesGSH,andparaquat,whichgeneratesO
−
2 [65].
Furthermore, since the overexpression of CLN3 conferred
resistance to OS in ﬂies, this gene might be used in vectors
[66], as a strategy that could increase its expression in ND.
The adaptation and survival of cells and organisms re-
quires the ability to sense proteotoxic insults and to co-
ordinate protective cellular stress response pathways and
chaperone networks related to protein quality control and
stability [26]. Inherited Friedreich ataxia (FRDA) is a neu-
rodegenerative disease characterized by a mutation of the
frataxin gene with disturbed iron function. This protein
serves as a chaperone in iron-sulphur cluster assembly, but
the mutation leads to mitochondrial free iron overload and
ROSformation[67].α-Tocotrienolquinoneseemstobepro-
tective in this disease, because it rescued primary ﬁbroblasts
from an FRDA patient from cell death induced by L-
buthionine-(S,R)-sulfoximine, which depletes GSH [68].
Ongoing FDA-approved, open-label human studies in
patients with inherited mitochondrial disease receiving α-
tocotrienol quinone at doses between 100–400mg three
times daily, no signiﬁcant elevation of clotting times or
signiﬁcant drug-related adverse events have been reported
[68].
Therefore, in the main ND, several genes are related to
mechanisms that generate ROS. On the other hand, some
genes seem to be important in the protections of neurons
against ROS, since neurodegeneration occurs when there are
mutations. It is important to know the involvement of genes
in neurodegeneration and in neuroprotection because they
can be targets for therapeutic approaches.
5. The Role of GlialCells
Neurons depend on glial cells to survive during all life, and it
is important to understand the functioning of these cells in
aging and ND. The glial cell line-derived neurotrophic factor
(GDNF) seems to play a physiological role in the mainte-
nance and function of the aging nigrostriatal system [69].
Riluzole induced GDNF mRNA expression and release via
ﬁbroblast growth factor receptor signaling in rat C6 glioma
cells, which are used as a model of astrocytes [70]. In ad-
dition, Nrf2 overexpressing transfected glial cells strongly
protected surrounding untransfected neurons [14]. The
treatment of C6 cells with 6-hydroxydopamine increased the
nuclear translocation and transcriptional activity of Nrf2,
which seemed to be partly mediated by activation of up-
stream kinases, such as Akt/protein kinase B (EC 2.7.10.2)
[71]. As it was stated before, Nrf2 regulates the expression of
several antioxidant enzymes.
Astrocytes express several enzymes of drug metabolism,
whichprotectneuronsagainstreactivexenobiotics. Ratbrain
microsomes were able to catalyze the glucuronidation of pla-
nar phenols [72]. Astrocytes keep glutamate and ammonia at
low levels in the CNS because these cells express glutamate-
ammonia ligase, more commonly known as glutamine
synthetase (GS; EC 6.3.1.2). However, OS and iron levels
in ND may interfere in the activity of this enzyme. The GS
activity in mouse astrocyte primary cultures is inhibited by
H2O2 at high concentrations, an eﬀect that was reverted8 Oxidative Medicine and Cellular Longevity
by iron chelators such as 1,10-phenanthroline and 2,2
 -
dipyridyl [73]. In addition, MAO-B is expressed in glial cells
and it can contribute to ROS generation. Cellular iron and
MAO levels are elevated in the aging brain and in brains
burdened with ND because of gliosis [74].
Activated glial cells are histopathological hallmarks of
ND. In response to neuronal injury, microglia and astrocytes
become activated and secrete inﬂammation mediators such
as cytokines, chemokines, and the potentially damaging NO
and ROS [34]. PD is associated with neuroinﬂammation, in
which the hallmarks are the presence of activated microglia
and reactive astrocytes in the parenchyma of the CNS, and
increased production of ROS and RNS that in some case can
result in disruption of the BBB [75]. Although ﬂavonoids
havebeenadoptedinpopularmedicineasantioxidants,rutin
is able to activate microglial cells in vitro at concentrations
above 50μM[ 76]. Alkaloids can also activate glial cells in
vitro and stimulate NO production [77]. The activation of
glial cells can be deleterious to neurons. The bacterial en-
dotoxin lipopolysaccharide causes dopaminergic neurode-
generation via activation of surrounding glial (mainly mi-
croglial) cells [69]. HNE, which results from lipid peroxi-
dation, upregulates cytosolic phospholipase A2 (PLA2)a n d
its phosphorylated activated form in cultured Ra2 microglial
cells [78]. PLA2 is a well-known proinﬂammatory enzyme.
The generation of ROS is not only deleterious to neurons.
Oligodendroglial cells are also highly susceptible to oxidative
damage. These cells have a high metabolic rate with toxic
by-products, an increased requirement for ATP, high intra-
cellular iron level, and low concentrations of GSH [79].
Although glial cells are physiologically very important for
neurons, these data show that in pathological conditions
their activation can lead no neuron demise. It is important
to understand the role of glial cells to neurodegeneration
becausetheycanbetargetsforthedevelopmentofnewdrugs
and therapeutical strategies.
6.WhatAretheMainAdvancesinTherapeutics?
Current therapeutic strategies in ND have focused mainly
on alleviating symptoms and improving quality of life. A
multifunctional treatment, with symptomatic and neuro-
protective properties, would be ideal to the patient, as the
probability of side eﬀects due to drug interactions would be
reduced, besides being more convenient [19]. Furthermore,
mounting evidence in the peer-reviewed literature shows
that the etiopathology of these diseases is extremely complex
and heterogeneous, resulting in signiﬁcant comorbidity and,
therefore, unlikely to be mitigated by any drug acting on a
single pathway or target [74]. The primary objective of neu-
roprotective therapies is to preventneuronal degeneration by
interfering in the underlying neurodegenerative mechanisms
that result in cell dysfunction and death [59]. It is important
to stress that a drug can have neuroprotective properties, but
be ineﬀective on neural restoration or neuro rescue, as these
eﬀects are accomplished by diﬀerent mechanisms of action.
Ideally, neuroprotective therapies should provide some pro-
tection against neurotoxins, ROS, and free radicals, besides
promoting neuronal survival through the upregulation of
neurotrophic factors [5]. However, the involvement of mul-
tiple pathways plus the absence of a reliable biomarker to
assess disease progression makes the evaluation of potential
neuroprotective treatments diﬃcult. Current animal models
do not replicate the disease process, such as in PD, and there
is no validated quantitative biomarker to assess disease pro-
gression in patients. In the absence of a reliable biomarker of
disease progression, some clinical trial strategies were devel-
oped in order to evaluate neuroprotective eﬀects of some po-
tential drugs. As the majority of these drugs are used to treat
symptomatically patients, and clinical trials do not assess
mechanisms of action, neuroprotective results may be con-
founded by potential symptomatic eﬀects of these medica-
tions.
7. MAO-B Inhibitors
Neurons of the substantia nigra pars compacta are more
susceptible to OS due to dopamine, melanin, and iron con-
centration. In addition, the dopamine metabolism by MAO-
B leads to formation of H2O2, which interacts with iron and
produces HO
•. Decreased levels of GSH were found in au-
topsy brains of PD patients [5], enhancing the role of OS
in neuronal death. MAO-B inhibition is associated with re-
duction on dopamine turnover and OS. In this context, a
randomized placebo-controlled trial called DATATOP (De-
prenyl [selegiline] And Tocopherol Antioxidant Therapy Of
PD) was developed to evaluate selegiline and Vitamin E
as potential disease-modiﬁcation therapies. PD patients in
earlystageswererandomlyassignedtothreegroups:placebo,
Vitamin E (2000IU) or selegiline (5mgBID), a MAO-B in-
hibitor. The primary endpoint was requirement of levodopa
therapy. The results showed that patients treated with selegi-
line had a signiﬁcant lower risk of reaching the endpoint
(26% in the selegiline group and 47% in the placebo group).
However, Vitamin E produced no beneﬁts and there was
no interaction between the two drugs [80]. Initially, these
ﬁndings were considered as a potential disease modiﬁcation
property of selegiline. However, at that time it was not con-
sidered that selegiline could have a small symptomatic eﬀect
responsible for these results. In order to solve these conﬂicts,
a study called SINDEPAR (Sinemet-Deprenyl-Parlodel) was
conductedinpatientswithearlyPD,designedwithawashout
period to clear symptomatic eﬀects of the drug and then
prove neuroprotection [81]. In this trial, patients were
randomly assigned to treatment with selegiline or placebo,
or to symptomatic treatment with bromocriptine or lev-
odopa. Patients were followed for 14 months, and selegiline
was stopped 2 months prior to endpoint. In addition, bro-
mocriptine and levodopa were stopped a week prior to end-
point. The primary endpoint was the change in motor uni-
ﬁed Parkinson’s disease rating scale (UPDRS) scores between
untreated baseline and ﬁnal visit, 2 months after a period
of selegiline withdrawal. The results showed that patients
treated with selegiline had lesser deterioration on UPDRS
scores than the placebo group, regardless of their symp-
tomatic treatment (levodopa or bromocriptine). Despite
these results, the doubt whether 2 months oﬀ selegiline
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remains.Consideringthedrugmechanismsofaction,ittakes
the brain about a month to turn over half of its MAO-B con-
tent. Therefore, it is possible that a protracted symptomatic
eﬀect could be still present in this clinical trial.
N-propargyl-1-(R)-aminoindan (rasagiline) is another
example of a MAO-B-targeting drug for use in ND. The pri-
mary eﬀect of rasagiline in PD is exerted by MAO-B inhi-
bition, thus leading to clearly symptomatic beneﬁts through
the reduced metabolism of endogenous and exogenous do-
pamine. Rasagiline has shown neuroprotective eﬀects in
ethanol-induced cell death mediated by a novel GAPDH-
MAO-B pathway [30]. The levels of cholesterol-oxidized
products and the depletion of GSH signiﬁcantly decreased in
the striatum of rats treated with rasagiline (0.05mg/kg daily
for 14 days) [82]. Although the evaluation of carcinogenicity
studies of rasagiline was positive in mice, which developed
lung adenoma and carcinoma, it is not relevant to humans
according to the European Public Assessment Reports
(EPAR) due to a high safety margin, since tumours were ob-
served at systemic exposures 144–213 times the expected
plasma levels in humans [83].
A delayed-start design wasdeveloped to assess the neuro-
protective properties of interventions by separating sympto-
matic from disease-modifying eﬀects. Studies with delayed-
start design are developed in two phases: initially, the groups
arerandomlyassignedtoreceiveeitheractivedrugorplacebo
for a period, followed by a phase in which all groups receive
the drug. The diﬀerences in the evolution of early versus late
onset of therapy are considered as disease-modifying eﬀects
exerted by the drug. Two studies, designed to overcome the
symptomatic eﬀects of rasagiline were included in this paper.
The TEMPO study (Rasagiline Mesylate [TVP-1012] in
Early Monotherapy for Parkinson’s Disease Outpatients) was
a randomized, double-blind, placebo-controlled trial de-
signedtoevaluatetheeﬀectsofearlyversuslaterasagilineuse
on progression of disability in PD patients [84]. This study
was carried out during one year with early-stage PD patients
who required no dopaminergic therapy, enrolled at 32 cen-
ters in the United States and Canada. In the ﬁrst phase,
lasting six months, 404 subjects were randomly assigned to
receive rasagiline (1 or 2mg/daily) or placebo. In the second
phase of treatment, patients who were on placebo entered
the active phase and received rasagiline (2mg/daily) for 6
months. The study compared the eﬀects of early versus late
rasagiline on PD progression. The primary endpoint was
change in total UPDRS score from baseline to 52 weeks later.
Secondary endpoints were the proportion of subjects whose
UPDRS score decreased by fewer than 4 units during the
study (classiﬁed as responders), change in the UPDRS motor
subscore, activities of daily living (ADL) subscore, and the
Beck Depression Inventory score. In a 26-week analysis, both
groups receiving rasagiline showed an improvement in the
meanUPDRStotalscore(1mg:4.2pointsmorethanplacebo
and 2mg: 3.5 points more than the placebo; P<0.00001).
In a posterior analysis performed at week 52, mean changes
in scores of total UPDRS score from baseline were 3.01
(SD 8.26), 1.97 (SD 7.49), and 4.17 (SD 8.83), in groups
treated with 1mg rasagiline, 2mg and late onset of 2mg,
respectively. The treatment eﬀect on the UPDRS total score
was evaluated by the diﬀerence in adjusted means of model
analysis of covariance. The comparison between the 1 mg
group and the late onset 2mg group was −1.82 units (95%
CI −3.64 to 0.01, P = 0.05). The comparison between the
2mg group with the late onset 2mg group resulted in −2.29
units (95% CI −4.11 to −0.48, P = 0.01). In the eﬃcacy
cohort, the percentages of individuals who were considered
as responders were 63.8% in the 2mg rasagiline for 1 year,
52.5%inthe1mgrasagilinefor1year,and52.3%inthe2mg
rasagiline delayed-start. Although statistically signiﬁcant, a
diﬀerence of just 1% in the UPDRS scale must be cautiously
interpreted as a clinical improvement.
The ADAGIO study (Attenuation of Disease Progression
with Azilect Given Once-daily) was a randomized, double-
blind, placebo-controlled, multicentre study carried out in
1176 untreated PD subjects in early stages of the disease,
during 72 weeks to evaluate whether the rasagiline therapy
slows the disease progression [85]. This study was conducted
in two phases, each one lasting 36 weeks. At ﬁrst, subjects
were randomly assigned into four groups to receive 1 or
2mg rasagiline/day, or corresponding placebo. In the second
phase, the subjects on the placebo group initiated the active
treatment phase, starting rasagiline (1 or 2mg/day; late on-
set), while the others continued to receive the doses previ-
ously established. The primary analysis consisted of three
hierarchical end points that assessed changes from baseline
in the total UPDRS score sections I through III. The ﬁrst end
point was measured from weeks 12 through 36 and showed
a slower progression rate in the rasagiline group treated with
1mg/day(0.09 ± 0.02 points per week), when compared to
placebo (0.14 ± 0.01 points per week; P = 0.01). The second
end point, assessed between baseline and week 72, showed
that the early-start group had less worsening in the mean
total UPDRS score when compared to the late-onset group
(2.82 ± 0.53 versus 4.50 ± 0.56 points; P = 0.02). The third
end point (week 48 through 72) showed the noninferiority
of the estimated changes in the total UPDRS score in the
early-onset group when compared to the late-onset group
(0.085±0.02 versus 0.085±0.02 points per week; P<0.001).
Among subjects receiving rasagiline (1mg/day) from the
beginning, all three end points previously established were
achieved. Among subjects receiving 2mg rasagiline from the
beginning, the rate of disease progression was also lower;
however, there was not a statistical signiﬁcant diﬀerence in
total UPDRS score when compared to the late-onset group
(3.47 ± 0.50 points versus 3.11 ± 0.50, P = 0.60).
Although it seems promising at a quick glance, the clini-
cal trials showing neuroprotective eﬀect of rasagiline should
beconsideredwithcaution.Thedelayed-starttrialdesignhas
several limitations that might interfere with study results,
such as the nonlinear progression of PD, the possibility
that all symptomatic drugs could produce positive results in
delayedstarttrials,thefragilityoftheUPDRSinassessingthe
outcomes, and the poor generalizability of results due to the
selectionofslowerdiseaseprogressionpatients. Thediﬀerent
results observed for the two doses of rasagiline are diﬃcult
to explain, but it is possible that a higher dose of rasagiline
may have preponderant symptomatic eﬀect and masked a
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disease. Another explanation is that neuroprotection can
follow a U-shaped curve, which could theoretically account
forthefailureofthe2mgdose[86].Furthermore,theclinical
meaning of a diﬀerence of just 1.7 units in the UPDRS score
is also questionable. It is clear that further studies addressing
the eﬀects of rasagiline on disease progression in PD patients
are required to support the positive ﬁndings for the 1mg
dose of rasagiline. The inclusion of subjects in a more ad-
vanced stage of the disease could help to diﬀerentiate the
symptomaticfromtheneuroprotectiveeﬀectsinhigherdoses
ofrasagiline.Inaddition,alongerfollowingupperiodwould
provide data on the persistent beneﬁts of the early-start
rasagiline on disease progression. At this moment, it is not
possible to establish the neuroprotective eﬀect of rasagiline
in PD patients using the existing evidence. However, even if
someone consider the crude results of these clinical trials, it
ishardtoconvincesomeonethatjust1%ofclinicalimprove-
ment is suﬃcient to aﬃrm the so-called neuroprotective
property of rasagiline. A recent trend in drug design and
discovery is the rational design or serendipitous discovery of
novel drug entities with the ability to address multiple drug
targets that form part of the complex pathophysiology of a
particular disease state [74]. Ladostigil is a multifunctional
compound designed to incorporate the cognitive enhancing
properties of rivastigmine with the neuroprotection proper-
ties of rasagiline [87]. However, it was not tested in clinical
trials, yet.
Lazabemide is a short-acting and reversible inhibitor
of MAO-B that is not metabolized into amphetamines. In
a randomized double-blinded and placebo-controlled trial,
321 untreated patients in early stages were assigned into
5 arms (placebo, 25mg/day, 50mg/day, 100mg/day and
200mg/day) and followed over one year [88]. In this study,
the risk of requiring levodopa therapy was reduced by 51%
in the lazabemide group when compared to placebo (P<
0.001), and the eﬀect was consistent among all dosages.
However, similarly to selegiline, lazabemide also have symp-
tomatic properties, which may have masked the results [89].
In preclinical models of HD, CEP-1347 showed promis-
ing results [60]. Therefore, a phase III double-blinded trial
was conducted in 806 early PD patients randomized into
fourarms(10mgBID ,25mgBID ,50mgBID ,orplacebo),
and the primary endpoint considered was time to levodopa
therapy. However, the study was interrupted earlier as there
were no signiﬁcant diﬀerences between placebo and CEP-
1347 groups in any endpoints considered [90].
8. AntiglutamatergicAgents
Preclinical studies have demonstrated the potential capacity
of riluzole to protect dopamine neurons [10, 91]. In order to
determine if riluzole has neuroprotective properties, a multi-
center placebo-controlled study was conducted in untreated
patients in early stages of PD. Patients were randomized to
receive 50mg riluzole capsules orally, taken twice daily, or
a matching placebo. After the washout period, all patients
were oﬀered a one-year open label extension study. Principal
endpoints were time required to levodopa therapy and
changes in UPDRS scale. Riluzole did not show signiﬁcant
neuroprotective eﬀects in any of the endpoints assessed [92].
9.AntioxidantsandVitamins
Substances that delay, prevent, or remove oxidative damages
to a target molecule are considered as antioxidants, but
eﬀorts to develop an eﬀective antioxidant treatment for ND
have remained elusive. Although Ginkgo biloba extract
protected cells against GSH depletion [12]a n dv i t a m i nE
is an antioxidant, the British Association for Psychophar-
macology considered that until further evidence is available,
they are not recommended either for the treatment or pre-
vention of AD [93]. Several new compounds cited in this
text that were tested in preclinical assays are not yet approved
by the U.S. Food and Drug Administration (FDA; http://
www.accessdata.fda.gov/scripts/cder/drugsatfda/). This is
case for extracts of L .ja p o n i c a ,E .ja p o n i c a ,a n dR. verniciﬂua,
the protein prosaposin, the synthetic compound 2-ethoxy-
4,5-diphenyl-1,3-oxazyne-6-one, and the ﬂavonoids bai-
calin, ﬁsetin, and quercetin. Melatonin, which has shown
antioxidant properties in vivo [15], sesamin, episesamin,
and their derivatives that induced antioxidant enzymes by
activating Nrf2/ARE signaling are not approved by the FDA,
too. However, in a randomized, placebo-controlled, cross-
over study, involving 24 postmenopausal healthy women,
sesame ingestion decreased total cholesterol and thiobar-
bituric acid reactive substances in LDL, meanwhile it in-
creased the ratio of α-a n dγ-tocopherol to total cholesterol
[94]. Although the ﬂavonoid resveratrol is not approved by
FDA,itisnowinearlystagesofclinicaltrials,butnotforND,
its eﬃciency has been tested in the cancer treatment [51].
Tanshinone IIA is also not approved by FDA, but emerging
experimental studies and clinical trials have demonstrated
atherogenesis prevention [95].
Actually,thepossible clinical usesofvitamins inND have
been studied. The supplementation of vitamin E or C for
3-4 years in men from Hawaii aged between 71 to 93 years
with dementia and cognitive dysfunction found that both
vitaminsimprovedcognitiveperformancealongwithprotec-
tiononlyagainstnon-ADdementia[96].Inametaanalysisof
three vitamin E clinical trials, four trials of coenzyme Q10,
and 1 study of glutathione, only the coenzyme Q10 trials
demonstrated some minor treatment beneﬁts in PD that
probablymaptopartialcorrectionofmitochondrialelectron
transport chain deﬁciency [96]. One prospective study failed
to ﬁnd an association between dietary folate, vitamin B12, or
vitamin B6 with incident AD [97]. Based on several clinical
trials showing that supplementation with folic acid with or
without vitamin B12 does not beneﬁt cognition in people
with dementia, the British Association for Psychopharma-
cology does not recommend their use either for dementia
treatment or prevention [93]. The possible clinical use of
vitamin D has also been investigated. Vitamin D promotes
health by regulating autophagy, which is a catabolic proc-
ess necessary for cells to degrade cytosolic macromolecules
and organelles in the lysosome [98]. Few double-blind
placebo-controlled prevention trials support the hypothe-
sis that calcipherol hormones are signiﬁcantly involved inOxidative Medicine and Cellular Longevity 11
several chronic ND and they could be used in preventive
medicine[99].However,morestudiesareneededbeforeﬁnal
conclusions can be made.
10.MetalChelators
Oxidativestresshasbeenatherapytargetinclinicaltrials,but
results have largely been negative or mild at best. However,
it is important to look for new metal chelators, since in a
clinical trial the licensed drug desferrioxamine was found to
reduce the rate of progression of AD by a factor of 2 within a
two-year period [100]. However, despite evidence showing
the involvement of metals in ND, a case-control study in
Japan found that a higher intake of iron, magnesium, and
zinc was independently associated with a reduced risk of
PD [101]. However, a weakness in this study is that control
subjects were signiﬁcantly younger than cases with PD.
Among other iron chelators, clioquinol is approved by FDA
for topical use as ointment in association with nystatin, but
t h i si sn om o r ef o u n do nm a r k e t i n gb e c a u s ei t sp r o d u c t i o n
was discontinued. Anyway, it was not approved to be used in
ND. Other metal chelators such as 1,10-phenanthroline and
2,2
 -dipyridyl that have been used in preclinical tests are not
approved by FDA.
11. Concluding Remarks
Investment in drug research and development has increased
in recent decades, but the annual number of truly innovative
new medicines has not increased accordingly, which creates
a problem to the pharmaceutical industry to replace the loss
of revenues due to patent expirations [102]. Despite evi-
dences that OS plays a role in ND, a good target for phar-
macological management rests to be determined. Although
ROS should be a therapeutic target in ND, this is necessary
to recognize that an antioxidant in chemical systems may be
not an eﬃcient agent in biological ones. The eﬀectiveness
of antioxidants is probably limited by their bioavailability
and the fact that they would have to be present at high con-
centrations to be able to compete with endogenous targets.
Several potential drugs have been screened using in vitro and
in vivo models of ND, but these results were not translated in
beneﬁt of patients, and disappointing results were obtained
in the majority of clinical trials. However, several potential
drugs and their targeted pathways were not yet tested in clin-
ical trials. Among the drugs tested in clinical trials, selegiline
andrasagiline are the most promising ones at least in PD,but
their neuroprotective eﬀects remain to be better investigated.
EvenifOSplaysacontributoryroletotheneurodegeneration
process, it is likely not the only pathological insult that needs
to be targeted.
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